Halogens ‒ particularly chlorine, bromine, and iodine -- have a unique quality which allows them to positively influence the interaction between molecules. This "halogen bonding" has been employed in the area of materials science for some time, but is only now finding applications in the life sciences.
Scientists at the University of Tübingen, in cooperation with the MRC Laboratory of Molecular Biology in Cambridge / UK, have now demonstrated that halogen bonding can be used to identify potential drug candidates for cancer treatment. Dr. Rainer Wilcken and Prof. Frank Böckler in collaboration with Dr. Andreas Joerger and Prof. Sir Alan Fersht, have presented a new concept of pharmaceutical research: fragment-based development of lead compounds based on halogen bonding.
The method uses specially designed fragment libraries to screen for binders to biological target structures such as proteins or DNA in order to develop new drugs.
To date, halogens -- particularly the heavier bromine and iodine -- have been underrepresented in such fragment libraries. Now, for the first time, scientists at the Pharmaceutical Institute at the University of Tübingen have described the design and application of halogen-enriched fragment libraries (HEFLibs) in the Journal of the American Chemical Society.
Cite This Page: